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ABSTRACT
Objectives. Interleukin-18 (IL-18) is a representative proinflammatory cytokine that plays an important role in 
the pathogenesis of rheumatoid arthritis (RA). The objective of this study was to evaluate the concentration 
of IL-18 in patients with RA in relation to RF IgM and anti-cyclic citrullinated peptide antibodies (anti-CCP2). 
Design and methods. 75 patients with diagnosed RA (aged 20–80 years) treated with non-steroidal anti- 
-inflammatory (NSAIDs) and disease modifying anti-rheumatoid drugs (DMARDs) and 52 age-matched 
controls were included.
Results. IL-18 concentration was almost sixfold higher in RA patients in comparison with the reference 
group (235 pg/mL v. 39 pg/mL). The association between IL-18 and RF IgM and anti-CCP was found.
Conclusions. Serum IL-18 level seems to be positively related to the increased RF IgM and anti-CCP 
concentrations in patients with established rheumatoid arthritis.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoim-
mune disease characterized by a chronic inflamma-
tion of the synovial joints that leads to a progressive 
degradation of the articular cartilage and bone. The 
etiology of RA remains still unknown, yet many stud-
ies have indicated that cytokines and inflammatory 
mediators are significantly involved in the pathogen-
esis of this disease. It is believed that the initiation 
of RA is associated with CD45RO+ T lymphocytes 
response and subsequent releasing of proinflam-
matory cytokines. The imbalance between pro- and 
anti-inflammatory cytokines in RA affects the active 
chronic inflammation and the tissue destruction in the 
joints of RA patients [1, 2]. 
Interleukin-18 (IL-18) is a representative proinflam-
matory cytokine and its role in RA has been extensively 
studied recently [3, 4]. It is acknowledged that IL-18 is 
a member of the IL-1 superfamily, which is synthesized 
as a precursor form (pro-IL-18), and its biological activity 
depends on the secreted IL-18 binding protein (IL-18BP) 
and its receptor (IL-18R) [5]. IL-18, first identified as an 
interferon gamma-inducing factor (IFN-g IF), stimulates 
the secretion of IFN-g and other inflammatory cytokines 
(TNF-a, IL-1b, IL-6) as well as chemotactic factors par-
ticipating in the acute-phase response, that play a key 
role in the regulation of immunity and inflammation in 
patients with RA [6, 7]. 
In particular, IL-18 is produced in RA by a number of 
cells such as macrophages, fibroblasts, articular chondro-
cytes and osteoblasts, therefore, it is suggested that IL-18 
is involved in the destruction of cartilage and bone [8]. 
Additionally, the administration of IL-18 increased 
the development of erosive, inflammatory arthritis in 
a mice model [1, 8]. Moreover, the increased con-
centrations of IL-18 were demonstrated in the serum, 
synovial fluid and synovial tissue of RA patients [3]. 
Notwithstanding these findings, the use of IL-18 as 
a possible biomarker of disease activity in RA is still 
controversial [9, 10]. 
Therefore, the aim of this study was to evaluate the 
serum concentration of interleukin-18 in patients diag-
nosed with RA. In addition, we examined the relationship 
between the concentration of IL-18 and the presence 
of rheumatoid factor IgM/ and anti-cyclic citrullinated 
peptide antibodies as well as the serum concentration 
of high-sensitivity C-reactive protein. 
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Materials and methods
Patients
The study group consisted of 75 patients (68 fe-
males and 7 males, aged 20–80 years) with the es-
tablished diagnosis of RA. Patients were recruited in 
the Rheumatology Outpatient Clinic of the University 
Hospital in Bydgoszcz, Poland. All these patients met 
the classification criteria of the American College of 
Rheumatology (ACR). Taking into account the positive 
or the negative result of RF IgM or anti-CCP, the pa-
tients were divided into two groups: seropositive and 
seronegative. The patients were also divided according 
to the Steinbrocker criteria into groups at four stages 
of the disease advancement: I (early) — 11 patients, 
II (moderate) — 35, III (severe) — 21 and IV (terminal) 
— 8 patients. In the entire study group the duration 
of the disease ranged from 1 to 25 years. Most RA 
patients received disease-modifying anti-rheumatic 
drugs (DMARDs), i.e. methotrexate, sulfasalazine, 
gold salts and non-steroidal anti-inflammatory drugs 
(NSAIDs) as well as glucocorticoids. 13 subjects were 
treated with DMARDs for the period ranging from 
2 months to 25 years, and 10 patients with NSAIDs 
for the period ranging from 8 months to 14 years. The 
combination therapy was applied in 11 patients for the 
period ranging from 3 months to 20 years (DMARDs 
and NSAIDs), in 19 patients (DMARDs and cortico-
steroids) and 9 patients (DMARDs, corticosteroids 
and NSAIDs) for the period ranging from 1 month to 
20 years. 13 RA patients received no pharmacological 
treatment. The clinically healthy volunteers (34 women 
and 18 men, aged 24–60 years) with no evidence of 
present inflammatory rheumatic diseases served as 
the reference group.
The study protocol was approved by the Bioethics 
Committee at the Nicolaus Copernicus University in 
Torun, Collegium Medicum in Bydgoszcz and it com-
plied with the World Medical Association Declaration 
of Helsinki regarding the ethical conduct of research 
involving human subjects. From all patients and controls 
an informed written consent was obtained.
Sample collection and analysis
Fasting venous blood samples from patients and 
controls were collected in the morning. The samples 
were centrifuged at 3000 g for 15 min, aliquoted, and 
stored at –80°C until assayed. 
The serum concentration of IL-18 was determined 
by the enzyme-linked immunosorbent assay (ELISA) 
(human IL-18 ELISA; Bender MedSystems, Vienna, 
Austria) in compliance with the manufacturer’s pro-
tocol. The method utilized anti-IL-18 monoclonal 
antibodies against human IL-18. Samples were run at 
a 1:2 dilution in an assay with standards ranging be-
tween 78.1 pg/mL and 5000 pg/mL. The sensitivity of 
the assay was 9.2 pg/mL and the reference range was 
from 55 to 280 pg/mL. The overall intra- and interassay 
coefficients of variation (CV) were 6.5% and 8.1% re-
spectively. IL-18 concentrations above 280 pg/mL were 
considered positive.
C-reactive protein (CRP) was measured with a high 
sensitivity assay using the BN II System nephelometer 
(N High-Sensitivity CRP; Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA), providing excellent precision with 
the CV, reported by the manufacturer, of less than 10%. 
CVs for hsCRP estimated in our laboratory were below 
3.5% and < 4.5% for the hsCRP concentrations below 
1 mg/L and above 3 mg/L respectively. The lower limit 
of hsCRP detection was 0.175 mg/L. The normal range 
of hsCRP was ≤ 3 mg/L. The results above 3 mg/L were 
considered positive. 
IgM rheumatoid factor was measured in serum us-
ing the commercially available enzyme immunoassay 
(IMTEC-IgM-RF; IMTEC Immundiagnostica GmbH, Ber-
lin, Germany). The standards ranged from 12.5 U/mL to 
200 U/mL. The results above 15 U/mL for RF IgM were 
considered positive. 
Anti-CCP2 antibodies were determined by ELISA 
(Anti-CCP ELISA [IgG]; Euroimmun, Luebeck, Germa-
ny) in accordance with the manufacturer’s instruction. 
This assay detects human autoantibody of the IgG 
class against the second generation cyclic citrullinated 
peptide (CCP2). The serum samples were assayed 
at a 100-fold dilution with standards ranging from 
0 RU/mL to 100 RU/mL (intraassay CV 2.9–7.3%, 
interassay CV 4.0–8.3%). The lower detection limit of 
the anti-CCP2 ELISA was 0.05 RU/mL and values over 
5 RU/mL were considered positive. 
Statistical analysis
The Kolmogorov-Smirnov test was used to assess 
the normality of distribution of the investigated para-
meters. Data were expressed as medians with the 
interquartile range (25th–75th percentiles) according to 
the distributions of continuous variables. The differenc-
es between the RA and control groups were analyzed 
by the Mann-Whitney U-test and the Kruskal-Wallis 
test for independent samples of non-parametric data, 
and then with the post-hoc Dunn’s test. The associ-
ation between the variables was calculated with the 
Spearman correlation coefficient. P values lower than 
0.05 were considered statistically significant. The sta-
tistical analysis and the sample size calculation were 
performed using Statistica 10.0 for Windows (StatSoft, 
Tulsa, OK, USA).
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Table 1. Clinical and laboratory characteristics of the study participants
Parameter RA patients
(n = 75)
Reference group  
(n = 52)
p
Age (years) 55 (46–65) 43.5 (28–50)  < 0.0001
Females n (%) 68 (91) 34 (65) 0.0001
Males n (%) 7 (9) 18 (35) 0.0001
Family history of RA, positive n (%) 42 (56) 0  < 0.0001
Other diseases n (%) 36 (48) 0 0.0003
Disease duration (years) 9.5 (5–16) NA NA
Duration of treatment (years) 7 (0.2–11.5) NA NA
Stage (Steinbrocker) n (%) 
   I
   II
   III
   IV
11 (15)
35 (47)
21 (28)
8 (10)
NA
NA
NA
NA
NA
NA
NA
NA
Treated with: n (%)
   DMARDs
   NSAIDs
   DMARDs and NSAIDs
   DMARDs and corticosteroids 
   DMARDs, corticosteroids and NSAIDs 
13 (17)
10 (13)
11 (15)
19 (25)
9 (12)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
Non-treated 13 (17) NA NA
IL-18 [pg/mL] 235 (88–428) 39 (20–68)  < 0.0001
CRP [mg/L] 2.86 (1.0–11.6) 0.62 (0.2–1.2)  < 0.0001
RF IgM [IU/mL] 16.8 (9.5–40.7) 3.8 (2.7–6.1)  < 0.0001
Anti-CCP [RU/mL] 1.99 (1.13–83.53) < 0.05*  < 0.0001
Anti-CCP — anti-cyclic citrullinated peptide antibody; CRP — C-reactive protein; DMARDs — disease-modifying anti-rheumatic drugs; IL-18 — inter- 
leukin 18; NA — not applicable; NSAIDs — non-steroidal anti-inflammatory drugs; RA — rheumatoid arthritis; RF — rheumatoid factor;  
RF IgM — rheumatoid factor in class M; *Anti-CCP below test’s sensitivity
Results
Baseline characteristics and results of basic 
statistics
Baseline characteristics of the RA patients and the 
control group including demographic data, clinical 
and laboratory parameters are shown in Table 1. All 
quantitative variables differed significantly between 
both investigated groups. Patients with RA, in compar-
ison with the reference group, had significantly higher 
concentrations of IL-18 and hsCRP as well as higher 
levels of RF IgM and anti-CCP2. Positive values of IL-18 
were found in 43%, RF IgM in 55%, whereas positive 
anti-CCP2 and hsCRP were found in 48% of patients. 
In the course of further analysis, RA patients were 
divided into groups on the basis of the laboratory pa-
rameters. RF IgM (+) patients showed significantly high-
er concentrations of IL-18, hsCRP and anti-CCP2 than 
RF IgM (–) patients. However, statistically significant differ-
ences between the anti-CCP2 (+) and the anti-CCP2 (–) 
groups were found only for IL-18 and RF IgM (Tab. 2). 
The correlation analysis showed significant re-
lationships between serum IL-18 concentration and 
other variables in the RA patients. Positive correlation 
was found for RF IgM (R = 0.54, p < 0.00001), age 
(R = 0.26, p = 0.007), hsCRP (R = 0.26, p = 0.02) and 
anti-CCP2 (R = 0.35, p = 0.002).
Discussion
Our study clearly demonstrated almost sixfold high-
er median concentration of IL-18 in patients with RA 
compared to the subjects in the reference group. Addi-
tionally, in almost half of the patients, the concentrations 
of IL-18 were above the levels accepted as normal. The 
concentration of IL-18 was elevated in seropositive RA 
patients. Moreover, our study revealed the association 
between IL-18 and other serological and inflammatory 
biomarkers of disease activity (RF IgM, anti-CCP2 and 
hsCRP serum levels). 
These results are in line with studies conducted by 
Shao [6] and Munakata [11]. The increased levels of 
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Table 2. The values of measured parameters in RF IgM/anti-CCP positive and negative RA patients
Parameter RF IgM(+)
(n = 40)
RF IgM(–)
(n = 35)
p
IL-18 [pg/mL] 368 (93–540) 132 (73–245) 0.0005
CRP [mg/L] 5.46 (1.88–14.25) 1.59 (0.68–4.84) 0.01
anti-CCP [RU/mL] 47.02 (1.81–106.36) 1.60 (0.65–1.69)  < 0.0001
Parameter anti-CCP(+)  
(n = 36)
anti-CCP(–)
(n=39)
p
IL-18 [pg/mL] 392 (179–533) 133 (63–248) 0.0001
CRP [mg/L] 4.96 (1.46–10.65) 2.36 (0.64–11.9)  NS
RF IgM [IU/mL] 39.10 (21.5–110.4) 9.90 (7.8–16.0)  < 0.0001
Anti-CCP — anti-cyclic citrullinated peptide antibody; Anti-CCP(+) — positive anti-cyclic citrullinated peptide antibody; Anti-CCP(–) — negative 
anti-cyclic citrullinated peptide antibody; CRP — C-reactive protein; IL-18 — interleukin 18; NS — not significant; RA — rheumatoid arthritis;  
RF IgM — rheumatoid factor in class M; RF IgM: RF IgM(+) — positive rheumatoid factor in class M; RF IgM(–) — negative rheumatoid factor in class M
serum IL-18 in patients with RA have also been observed 
in other studies [12, 13].
The increased levels of IL-18 are primarily associated 
with chronic inflammation in the autoimmune diseases [14]. 
IL-18, described for the first time by Gracie et al. [15, 16], 
was significantly elevated in the rheumatoid synovium, 
which may confirm its contribution to the development 
of arthritis in RA and the destruction of cartilage [17, 18]. 
According to Joosten et al. [19], elevated IL-18 lev-
els are detected in 80% of patients with RA, which 
may result from the association between IL-18 gene 
polymorphisms and the occurrence of individual sus-
ceptibility to RA [1, 8, 12], but the exact contribution 
of genetic predisposition to the RA development has 
not been well recognized and needs further research. 
Additionally, the markedly higher IL-18 concentration in 
RA than in OA [20] and psoriatic arthritis [21] indicates 
the increased local production of this cytokine [20]. High 
expression of IL-18 by synoviocytes in RA may regulate 
the production of pathogenic cytokines responsible for 
the local inflammatory process [10]. 
In our study, seropositive RA patients were charac-
terized by higher concentrations of IL-18 than seroneg-
ative RA patients, which is consistent with other reports 
and may suggest that IL-18 can be a sensitive marker 
for monitoring disease activity [20, 21]. Autoantibody 
production in patients is a common symptom of RA [22]. 
Currently, RF and anti-CCP antibodies are the gold 
standard in the diagnosis of RA, and, due to the high 
sensitivity and specificity, are incorporated into the ACR 
classification criteria for RA [22–24]. Also, the synovial 
tissue from anti-CCP positive patients expresses higher 
concentration of immune cytokines and shows a greater 
degree of joint destruction than the tissue from anti-CCP 
negative patients [25, 26]. These findings are in agree-
ment with our observation that IL-18 levels correlate with 
the serological markers of disease activity (anti-CCP 
and RF IgM). On the contrary, Chang et al. [27] have 
not found any significant relationship between serum 
IL-18 and RF, thus the role of IL-18 as a marker of dis-
ease activity is still controversial and requires further, 
extended studies.
Currently, CRP is one of the best indicators of the 
acute phase response to inflammation [28]. Indeed, 
it is widely acknowledged that the serum CRP con-
centrations are typically increased during a disease, 
making this inflammatory biomarker very useful for the 
diagnosis and monitoring of RA.
Some researchers did not present a statistically 
significant correlation between the serum IL-18 levels 
and the CRP concentration, thus suggesting that IL-18 
may have a limited ability to induce acute phase 
proteins and other mediators of the inflammation. Fur-
thermore, the slight decrease in the concentration of 
IL-18 following anti-rheumatic drug therapy, in contrast 
to CRP, may suggest that the acute phase response 
may be largely independent of IL-18 [21]. However, 
we demonstrated a statistically significant correlation 
between the level of IL-18 and hsCRP concentration. 
In patients with RA the inflammatory process of insig-
nificant intensity may occur, thus it seems reasonable 
to measure CRP with a high sensitivity assay [29, 30]. 
The correctness of the choice of this assay for the 
determination of CRP is corroborated by the fact that 
the concentration of hsCRP above 3 mg/l was found in 
only 48% of patients with RA. Our results suggest that 
the determination of CRP, which is, in fact, the most 
recommended marker of the acute inflammation in 
RA, by means of using a high sensitivity assay may be 
useful to monitor the course of disease in RA patients, 
which was also previously suggested by other authors 
[22, 29, 31].
According to Chang et al. [17], IL-18 levels may cor-
relate with the indicators of local inflammatory response. 
Moreover, in patients with advanced RA, in addition to 
IL-18 and CRP, the increased concentrations of other 
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proinflammatory cytokines, such as IL-15 and TNF-a, 
were found in the serum and the synovial fluid [21]. 
Rooney et al. [32] have also observed an increased 
expression of IL-18 in the synovium of RA patients 
compared to patients with OA. Furthermore, the ex-
pression of IL-18 in the articular synovial tissue does 
not correlate with the serum IL-18 concentration [33]. In 
contrast, in another study, a significant relationship was 
found with other cytokines, such as IL-1b and TNF-a, 
and also CRP, which may suggest that the expression 
of IL-18 is associated with other cytokines and with 
the local inflammatory process in the synovium of RA 
patients [32, 34]. Additionally, its increased concen-
tration in the synovium correlates with the acute phase 
response, which demonstrates that IL-18 is a major 
proinflammatory cytokine in RA, thus leading to a local 
production of IL-1b and TNF-a involved in the synthesis 
of C-reactive protein [19].
Although among inflammatory biomarkers only 
CRP is recommended as a useful parameter of disease 
activity and treatment response, it is recognized that 
the combination of biomarkers will greatly facilitate 
the diagnosis of RA. International guidelines recom-
mend the use of anti-CCP, RF and CRP as the most 
useful combination of biomarkers in RA [23, 25]. The 
fact whether the addition of IL-18 to a combination of 
anti-CCP and RF IgM might have an added value and 
a beneficial impact on the diagnosis and evaluation 
of disease activity still requires further studies. How-
ever, our results indicate that this marker has certain 
potential and its diagnostic value in RA has not been 
comprehensively used so far.
Our study has some limitations to be considered. 
Our results in this study should be carefully interpreted 
because the number of subjects included was relatively 
small. However, this is a preliminary study which we 
intend to continue further.
Conclusion
This study implies that IL-18 is associated with the 
joint inflammation and the cartilage destruction in RA 
patients, but the exact mechanism of this pathway is not 
well understood and needs further studies. The elevated 
IL-18 concentration in RA, especially in seropositive in-
dividuals, suggests that IL-18 could possibly represent 
an important biomarker, which may be clinically relevant 
for the development of the new diagnostic strategy. 
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